Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 226

Sort by

Sort Order Select

Journal Articles

Taking aim at IDH in fitter patients with AML

Andrew H. Wei, Naval Daver

Blood (2021) 137 (13): 1706–1707.

https://doi.org/10.1182/blood.2020009361

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Xiaotian Zhang, Xinyu Wang, Xue Qing David Wang, Jianzhong Su, Nagireddy Putluri, Ting Zhou, Ying Qu, Mira Jeong, Anna Guzman, Carina Rosas, Yun Huang, Arun Sreekumar, Wei Li, Margaret A. Goodell

Blood (2020) 135 (11): 845–856.

https://doi.org/10.1182/blood.2019003330

Published: 2020

Includes: Supplemental data

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance

Blood (2019) 134 (Supplement_1): 233.

https://doi.org/10.1182/blood-2019-124535

Published: 2019

Journal Articles

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 4599.

https://doi.org/10.1182/blood-2019-131011

Published: 2019

Journal Articles

Comparison of Three Assays for Identification of IDH Mutations in AML

Sara Ribeiro, BSc, Dorte Wren, PhDFRCPath, Lisa Thompson, PhD MSc, FIBMS, Michael Hubank, PhD, David Taussig, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 5195.

https://doi.org/10.1182/blood-2019-126494

Published: 2019

Journal Articles

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Jordan Gales, MD, Matthew S. McKinney, MD, Harry P. Erba, MD PhD, Chad M. McCall, MD PhD

Blood (2019) 134 (Supplement_1): 5131.

https://doi.org/10.1182/blood-2019-125135

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 3360.

https://doi.org/10.1182/blood-2019-126580

Published: 2019

Journal Articles

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Guillaume Richard-Carpentier, MD, Amy E. DeZern, MD, Koichi Takahashi, MD, Marina Y Konopleva, MD PhD, Sanam Loghavi, MD, Lucia Masarova, MD, Yesid Alvarado, MD, Farhad Ravandi, MD, Guillermo Montalban Bravo, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ricardo Delumpa, BSN, Monica Kwari, BSN, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 678.

https://doi.org/10.1182/blood-2019-130501

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Blood (2019) 134 (Supplement_1): 3720.

https://doi.org/10.1182/blood-2019-129276

Published: 2019

Journal Articles

Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of TET2 Mutant AML

Ellie Wilson, BS, Nichole Helton, Catrina Fronick, BS, Robert Fulton, MS, John S. Welch, MD PhD, Timothy J Ley, MD, David H Spencer, MD

Blood (2019) 134 (Supplement_1): 3755.

https://doi.org/10.1182/blood-2019-122340

Published: 2019

Journal Articles

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Giovanni Marconi, Roberta di Nicola, Chiara Sartor, MD, Mariachiara Abbenante, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Sarah Parisi, MD PhD, Carmen Baldazzi, PhD, Maria Chiara Fontana, PhD, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli, MD, Michele Baccarani, MD, Cristina Papayannidis, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2617.

https://doi.org/10.1182/blood-2019-130630

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Sebastian Vosberg, Paul Kerbs, MSc, Vindi Jurinovic, MSc, Klaus H. Metzeler, MD, Susanne Amler, PhD, Cristina Sauerland, Dennis Görlich, PhD, Wolfgang E. Berdel, MD, Jan Braess, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD, Philipp A. Greif, MD PD

Blood (2019) 134 (Supplement_1): 2715.

https://doi.org/10.1182/blood-2019-130047

Published: 2019

Journal Articles

Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Sanghee Hong, MD, Cassandra M Kerr, MS, Lisa Rybicki, MS, Valeria Visconte, PhD, Jibran Durrani, Hassan Awada, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Aaron T. Gerds, MD MS, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, MD, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2716.

https://doi.org/10.1182/blood-2019-130352

Published: 2019

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Blood (2019) 134 (Supplement_1): 2091.

https://doi.org/10.1182/blood-2019-128066

Published: 2019

NARROW

Taking aim at IDH in fitter patients with AML

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Comparison of Three Assays for Identification of IDH Mutations in AML

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of TET2 Mutant AML

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only